7 Supplementary Tables; 16 Supplementary Figures from Development and Validation of a Novel Signature to Predict Overall Survival in “Driver Gene–negative” Lung Adenocarcinoma (LUAD): Results of a Multicenter Study
Authors: Cui Yongmei , Fang Wenfeng , Li Chaofeng , Tang Kejing , Zhang Jian , Lei Yiyan , He Weiling , Peng Sui , Kuang Ming , Zhang Hui , Chen Lili , Xu Di , Tang Cuilan , Zhang Wenhui , Zhu Yuxin , Jiang Wenting , Jiang Neng , Sun Yu , Chen Yangshan , Wang Han , Lai Yingrong , Li Shuhua , He Qiong , Zhou Jianwen , Zhang Yang , Lin Millicent , Chen Honglei , Zhou Chenzhi , Wang Chunlin , Wang Jianhong , Zou Xuenong , Wang Liantang , Ke Zunfu 
Published: April 2023

<p>Supplementary Table S1 shows the list of primary antibodies used for immunohistochemical staining and immunoblotting assays. Supplementary Table S2 shows the clinical characteristics of 626"driver-gene-negative" LUAD patients from four cohorts. Supplementary Table S3 shows the clinical characteristics of 52 "driver-gene-negative" LUAD patients whose samples were used for microarray analysis. Supplementary Table S4 shows the microarray results of the genes in the Wnt-signaling pathway. Supplementary Table S5 shows the univariate association of 41 candidate genes with overall survival in the training SYSUFH cohort. Supplementary Table S6 shows the C-index of the three enrolled factors in the nomogram in the SYSUFH training cohort. Supplementary Table S7 indicates the summary of relevant findings of ITH analysis of twenty-one patients with "driver-gene-negative" LUAD. Supplementary Figure S1 shows the workflow to determine "driver-gene-negative" status in LUAD patients. Supplementary Figure S2 shows the pathological diagnosis of enrolled LUAD patients. Supplementary Figure S3 shows the study flowchart. Supplementary Figure S4 shows the signaling GO analysis and cellular component classification analysis for the genome-wide microarray. Supplementary Figure S5 shows the β-Catenin expression characteristics in patients with "driver-gene-negative" LUAD from the SYSUFH training cohort. Supplementary Figure S6 shows the different expression profiles of β-catenin in EGFRmt, KRASmt, and ALKft LUAD. Supplementary Figure S7 shows the protein expression characteristics of 41 candidate genes in 8 "driver-gene-negative" LUAD patients. Supplementary Figure S8 shows these representative immunohistochemical staining for 41 candidate molecules in 626 "driver-gene-negative" LUAD patient tissue samples. Supplementary Figure S9 shows kaplan-Meier estimates of progression-free survival (PFS) based on the CSDW signature in the four cohorts. Supplementary Figure S10 shows that the CSDW signature predicts clinical outcomes in all 626 patients with "driver-gene-negative" LAUD. Supplementary Figure S11 shows that the optimum cutoff value of the four prognostic markers was determined using the X-tile program in the training set and Kaplan-Meier analysis of all 626 LUAD samples. Supplementary Figure S12 shows the correlation between the four genes in the CSDW signature and tumor size, lymphatic metastasis and distant organ metastasis. Supplementary Figure S13 shows that kaplan-Meier analysis was used to compare the performance of the CSDW signature in all 626 LUAD patients with different clinicopathological risk factors. Supplementary Figure S14 shows that the nomogram to predict the 3-year and 5-year overall survival (OS) of "driver-gene-negative" LUAD patients. Supplementary Figure S15 shows that time-dependent ROC curves to evaluate the sensitivity and specificity of the nomogram in predicting overall survival in "driver-gene-negative" LUAD patients. Supplementary Figure S16 shows that intra- and inter-sample variability of β-catenin, SOX9, DVL3 and Wnt2b protein levels detected by IHC.</p>